Valeria Cernaro, Davide Bolignano, Valentina Donato, Antonio Lacquaniti, Antoine Buemi, Eleonora Crascì, Silvia Lucisano and Michele Buemi Pages 844 - 849 ( 6 )
NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
NGAL,acute renal failure,chronic kidney disease,clinical nephrology,clinical pharmacology,glomerulonephritis,vasculitis,antimicrobial,gentamicin,microalbuminuria,Crohn's disease,flogistic,Infliximab,idiopathic,streptozotocin,angiotensin,sepsis,inefficacy,etiologic,immunosuppressors
, , , , , , , Via Salita Villa Contino, 30, 98100 Messina, Italy.